Multiple SclerosisArchives
An expanded polyglutamine in ATAXIN1 results in a loss-of-function that exacerbates severity of Multiple Sclerosis in an EAE mouse model
Multiple Sclerosis 6 min.
Expansion of the polyglutamine tract in ATAXIN1 (ATXN1), a nuclear protein [1], causes spinocerebellar ataxia type 1 (SCA1), a heritable neurodegenerative disorder [2, 3]. Neuroinflammation is a common feature of neurodegenerative disorders [4, 5–6]. Recently, the ATXN1 gene was identified...
Isolated Uhthoff phenomenon as first manifestation of multiple sclerosis: a case report
Multiple Sclerosis 3 min.
The Uhthoff phenomenon (UP) describes a temporary worsening of neurological symptoms due to an increase in body temperature in demyelinating diseases, most frequently observed in multiple sclerosis (MS) [1]. MS is an inflammatory demyelinating disease of the central nervous system and one of the most...
The Kappa Free Light Chains Index and Central Vein Sign: Two New Biomarkers for Multiple Sclerosis Diagnosis
Multiple Sclerosis 8 min.
The diagnostic criteria for multiple sclerosis (MS) have evolved over the years. The 2017 revision [1] combines clinical, imaging, and biological evidence and is widely used in clinical practice. They allow MS to be diagnosed early, after the first clinical event suggestive of the disease in most patients...
Primary central nervous system tumors in patients with multiple sclerosis
Multiple Sclerosis 3 min.
Given the widespread use of immunomodulatory therapies in individuals with multiple sclerosis (pwMS), assessing the prevalence and frequency of cancer within this population is crucial. However, studies across various registries have reported differing conclusions regarding cancer frequency. The increased...
Pyoderma gangrenosum in a patient with multiple sclerosis under natalizumab treatment: a case report
Multiple Sclerosis 2 min.
Multiple sclerosis (MS) is a chronic inflammatory disease of central nervous system and the most common progressive neurological disorder among young adults [1, 2]. Disease-modifying drugs (DMDs) have altered the long-term prognosis of the condition and enhanced patients’ quality of life [3]. Although...
